Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Resectable Stage II-IIIA Non-small Cell Lung Cancer
NCT07554846Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- May 2026
- Primary completion
- May 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Fudan University. Primary endpoint: Event-Free Survival at 3 years. Started May 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07554846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554846.